期刊
ALLERGY
卷 76, 期 1, 页码 14-44出版社
WILEY
DOI: 10.1111/all.14425
关键词
biologicals; cost-effectiveness; GRADE; guidelines; severe asthma
资金
- Swiss National Science Foundation, Christine Kuhne-Center for Allergy Research and Education, European Commission
- Cure
- AstraZeneca
- Genentech
- Novartis
- Sanofi Regeneron
- Amgen
- Genentech/Roche
- Stallergenes
- Teva
- GSK
- Innovation Fund Denmark
- Regeneron
- Regeneron, Ena Therapeutics
- Sanofi Genzyme
- Sunovion
- Mylan
- Asthma UK, Food Standards Agency
- AZ
- Roche
- AHL
- Nutricia
- Boehringer Ingelheim
- Gerolymatos International SA
- Mundipharma, Zambon
- Sanofi/Regeneron
- Fondazione Maugeri, Fondazione Chiesi and Edmond Pharma
- Chiesi
- Sanofi
- Mundipharma, Esteve
- Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics
- Circassia
- ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma
- Anergis SA, Mobile Chamber Experts
- Med Update Europe GmbH
- Mundipharma
- ASIT Biotech.sa, Allergy Therapeutics
- Allergopharma
- Inmunotek SL
- ALK-Abello, Allergopharma
- Anergis
- Vectura
- MedImmune
Severe asthma poses significant challenges in management, but targeted treatments with biologicals offer new hope for patients. However, further research is needed on issues such as selection of biologicals, response definition, treatment duration, and cost-effectiveness.
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据